| Sclerostin stimulates osteocyte support of osteoclast activity by a RANKL-dependent pathway AR Wijenayaka, M Kogawa, HP Lim, LF Bonewald, DM Findlay, GJ Atkins PloS one 6 (10), e25900, 2011 | 582 | 2011 |
| Biocompatible polymer coating of titania nanotube arrays for improved drug elution and osteoblast adhesion K Gulati, S Ramakrishnan, MS Aw, GJ Atkins, DM Findlay, D Losic Acta biomaterialia 8 (1), 449-456, 2012 | 351 | 2012 |
| Metabolism of vitamin D3 in human osteoblasts: evidence for autocrine and paracrine activities of 1α, 25-dihydroxyvitamin D3 GJ Atkins, PH Anderson, DM Findlay, KJ Welldon, C Vincent, ... Bone 40 (6), 1517-1528, 2007 | 345 | 2007 |
| RANKL expression is related to the differentiation state of human osteoblasts GJ Atkins, P Kostakis, B Pan, A Farrugia, S Gronthos, A Evdokiou, ... Journal of Bone and Mineral Research 18 (6), 1088-1098, 2003 | 308 | 2003 |
| Osteoprotegerin and receptor activator of nuclear factor kappaB ligand (RANKL) regulate osteoclast formation by cells in the human rheumatoid arthritic joint DR Haynes, TN Crotti, M Loric, GI Bain, GJ Atkins, DM Findlay Rheumatology 40 (6), 623-630, 2001 | 298 | 2001 |
| Sclerostin is a locally acting regulator of late‐osteoblast/preosteocyte differentiation and regulates mineralization through a MEPE‐ASARM‐dependent mechanism GJ Atkins, PS Rowe, HP Lim, KJ Welldon, R Ormsby, AR Wijenayaka, ... Journal of Bone and Mineral Research 26 (7), 1425-1436, 2011 | 291 | 2011 |
| Receptor activator of nuclear factor-κB ligand expression by human myeloma cells mediates osteoclast formation in vitro and correlates with bone destruction in vivo AN Farrugia, GJ Atkins, LB To, B Pan, N Horvath, P Kostakis, DM Findlay, ... Cancer research 63 (17), 5438-5445, 2003 | 275 | 2003 |
| The proliferation and phenotypic expression of human osteoblasts on tantalum metal DM Findlay, K Welldon, GJ Atkins, DW Howie, ACW Zannettino, D Bobyn Biomaterials 25 (12), 2215-2227, 2004 | 271 | 2004 |
| The osteoclastogenic molecules RANKL and RANK are associated with periprosthetic osteolysis DR Haynes, TN Crotti, AE Potter, M Loric, GJ Atkins, DW Howie, ... The Journal of Bone & Joint Surgery British Volume 83 (6), 902-911, 2001 | 262 | 2001 |
| Strontium ranelate treatment of human primary osteoblasts promotes an osteocyte-like phenotype while eliciting an osteoprotegerin response GJ Atkins, KJ Welldon, P Halbout, DM Findlay Osteoporosis International 20, 653-664, 2009 | 261 | 2009 |
| Osteocytes: the master cells in bone remodelling M Prideaux, DM Findlay, GJ Atkins Current opinion in pharmacology 28, 24-30, 2016 | 251 | 2016 |
| Osteoprotegerin expression in synovial tissue from patients with rheumatoid arthritis, spondyloarthropathies and osteoarthritis and normal controls DR Haynes, E Barg, TN Crotti, C Holding, H Weedon, GJ Atkins, ... Rheumatology 42 (1), 123-134, 2003 | 241 | 2003 |
| Osteoprotegerin (OPG) is localized to the Weibel‐Palade bodies of human vascular endothelial cells and is physically associated with von Willebrand factor ACW Zannettino, CA Holding, P Diamond, GJ Atkins, P Kostakis, ... Journal of cellular physiology 204 (2), 714-723, 2005 | 238 | 2005 |
| Expression of osteoclast differentiation signals by stromal elements of giant cell tumors GJ Atkins, DR Haynes, SE Graves, A Evdokiou, S Hay, S Bouralexis, ... Journal of Bone and Mineral Research 15 (4), 640-649, 2000 | 235 | 2000 |
| Osteocyte regulation of bone mineral: a little give and take GJ Atkins, DM Findlay Osteoporosis international 23, 2067-2079, 2012 | 227 | 2012 |
| Osteoclastic Metabolism of 25(OH)-Vitamin D3: A Potential Mechanism for Optimization of Bone Resorption M Kogawa, DM Findlay, PH Anderson, R Ormsby, C Vincent, HA Morris, ... Endocrinology 151 (10), 4613-4625, 2010 | 210 | 2010 |
| Pro‐inflammatory cytokines TNF‐related weak inducer of apoptosis (TWEAK) and TNFα induce the mitogen‐activated protein kinase (MAPK)‐dependent expression of sclerostin in human … C Vincent, DM Findlay, KJ Welldon, AR Wijenayaka, TS Zheng, ... Journal of bone and mineral research 24 (8), 1434-1449, 2009 | 210 | 2009 |
| Chemotherapeutic agents sensitize osteogenic sarcoma cells, but not normal human bone cells, to Apo2L/TRAIL‐induced apoptosis A Evdokiou, S Bouralexis, GJ Atkins, F Chai, S Hay, M Clayer, DM Findlay International journal of cancer 99 (4), 491-504, 2002 | 196 | 2002 |
| Bril: a novel bone‐specific modulator of mineralization P Moffatt, MH Gaumond, P Salois, K Sellin, MC Bessette, É Godin, ... Journal of bone and mineral research 23 (9), 1497-1508, 2008 | 195 | 2008 |
| TWEAK is a novel arthritogenic mediator SJ Perper, B Browning, LC Burkly, S Weng, C Gao, K Giza, L Su, ... The Journal of Immunology 177 (4), 2610-2620, 2006 | 193 | 2006 |
david findlayProfessor of Orthopaedic Research, University of AdelaidePotvrđena adresa e-pošte na adelaide.edu.au
